Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19592061 | 0.80 | MDM2 (0.34) | MAPTMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL18482876 | 0.77 | MEN1 (0.49) | MAPTMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL16168590 | 0.71 | PKM (0.44) | MAPTMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL13696451 | 0.71 | CRHR1 (0.49) | MAPTMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL18159968 | 0.70 | ALDH1A1 (0.40) | MEN1KMT2ANR3C1 | |
| SCHEMBL284551 | 0.70 | MAPT (0.46) | MAPTMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL16168602 | 0.70 | MAPT (0.43) | MAPTMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL24758266 | 0.70 | MEN1 (0.46) | MAPTMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL22667106 | 0.69 | CRHR1 (0.50) | MAPTMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL24014820 | 0.68 | MAPT (0.37) | MAPTMEN1RAB9AKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815791-B2 | Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160304465-A1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304465-A1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | MAPT 4100/4885MEN1 3903/4885RAB9A 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.